6HN.F EVEREST MED.LTD DL-0001
- Market cap
- EUR 1.05B
- P/E
- -
- P/B
- 1.51x
- ROE
- -5.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 6HN.F undervalued?
Graham numberThe Graham number of EVEREST MED.LTD DL-0001 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
EVEREST MED.LTD DL-0001 fundamental analysis
No fundamental analysis for EVEREST MED.LTD DL-0001 yet.
EVEREST MED.LTD DL-0001 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About EVEREST MED.LTD DL-0001
Everest Medicines Limited, a biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets. It pipeline includes Nefecon, an oral formulation of budesonide for the treatment of immunoglobulin nephropathy (IgAN); Xerava, a fully synthetic fluorocycline intravenous antibiotic for the treatment of infections caused by susceptibl…
Full company profileEVEREST MED.LTD DL-0001 financial statements
EVEREST MED.LTD DL-0001 annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 54.0K | 12.8M | 126M | 707M | 1.71B |
| Gross Profit | 31.0K | 8.15M | 91.5M | 527M | 1.18B |
| Operating Income | -1.05B | -1.40B | -832M | -744M | -371M |
| EBITDA | - | -199M | -745M | -886M | -419M |
| Net Income | -1.01B | -247M | -844M | -1.04B | -298M |
| EPS | -3.43 | -0.81 | -2.64 | -3.21 | -0.84 |
| Balance Sheet | |||||
| Total Assets | 6.65B | 6.61B | 5.77B | 4.96B | 6.83B |
| Total Liabilities | 754M | 960M | 804M | 886M | 1.53B |
| Shareholders' Equity | 5.89B | 5.65B | 4.97B | 4.07B | 5.30B |
| Cash & Short-term Investments | 2.64B | 491M | 523M | 884M | 1.84B |
| Cash Flow | |||||
| Operating Cash Flow | -730M | -1.16B | -769M | -680M | -92.6M |
| Capital Expenditure | 976M | 433M | 266M | 204M | 348M |
| Free Cash Flow | -1.71B | -1.59B | -1.04B | -884M | -441M |
| Ratios | |||||
| ROE | -17.1% | -4.4% | -17.0% | -25.6% | -5.6% |
| ROA | -15.2% | -3.7% | -14.6% | -21.0% | -4.4% |
| Net Profit Margin | -1,867,998.1% | -1,933.1% | -670.6% | -147.4% | -17.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
EVEREST MED.LTD DL-0001 dividends
EVEREST MED.LTD DL-0001 has not paid dividends in the last 5 fiscal years.
Who owns EVEREST MED.LTD DL-0001
- Insiders 5.94%
- Institutions 41.86%
- Public & others 52.20%
- Shares outstanding 354M
- Free float 219M
EVEREST MED.LTD DL-0001 company profile
- Company name
- EVEREST MED.LTD DL-0001
- Ticker
- 6HN.F
- ISIN
- KYG3224E1061
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 812
- Fiscal year end
- December
- Address
- AIA Financial Center, 17/F, Shanghai, China, 200082
- Website
- everestmedicines.com
About EVEREST MED.LTD DL-0001
Everest Medicines Limited, a biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets. It pipeline includes Nefecon, an oral formulation of budesonide for the treatment of immunoglobulin nephropathy (IgAN); Xerava, a fully synthetic fluorocycline intravenous antibiotic for the treatment of infections caused by susceptible gram-positive, gram-negative, and anaerobic pathogens; Taniborbactam, a beta-lactamase inhibitor (BLI) which is in phase 3 clinical trial for the treatment of patients with serious bacterial infections; and Etrasimod, an oral selective sphingosine 1-phosphate (S1P) receptor modulator which is in phase 3 clinical trial for to treat moderate-to-severe active ulcerative colitis. The company provides Zetomipzomib, an immunoproteasome inhibitor that is in phase 2b clinical trial, for a range of immune mediated disorders, including lupus nephritis; EVER001, a covalent reversible Bruton's tyrosine kinase (BTK) inhibitor which is in the phase 1b clinical trial for the treatment of renal diseases; and mRNA platform therapeutic vaccines for cancer and autoimmune diseases. Further, it offers EVER206, a polymyxin derivative designed to treat f MDR gram negative bacterial infections reduce toxicity and nephrotoxicity which is in phase 1 of clinical trial. The company was incorporated in 2017 and is based in Shanghai, China.
EVEREST MED.LTD DL-0001 management
10- Mr. Yifang WuExecutive Chairman of the Board · born 1969
- Mr. Yongqing LuoCEO & Executive Director · born 1970
- Mr. Ying WooCFO, President & Executive Director · born 1973
- Mr. Wenjun LiuCo-President & Chief Commercial Officer · born 1990
- Mr. Chonggang XuChief Operations Officer · born 1969
- Dr. Wei Yang Ph.D.Chief Scientific Officer · born 1970
- Dr. Jason M. Brown Ph.D.Chief Business Officer · born 1973
- Mr. Xu LiangChief Product Officer · born 1969
- Dr. Lakshmi Srinivasan Ph.D.Senior Vice President & Head of Translational Medicine
- Ms. Yee Wa LauJoint Company Secretary · born 1973